256 related articles for article (PubMed ID: 17227913)
1. Mechanism of thioamide drug action against tuberculosis and leprosy.
Wang F; Langley R; Gulten G; Dover LG; Besra GS; Jacobs WR; Sacchettini JC
J Exp Med; 2007 Jan; 204(1):73-8. PubMed ID: 17227913
[TBL] [Abstract][Full Text] [Related]
2. Bacterial Genome-Wide Association Identifies Novel Factors That Contribute to Ethionamide and Prothionamide Susceptibility in Mycobacterium tuberculosis.
Hicks ND; Carey AF; Yang J; Zhao Y; Fortune SM
mBio; 2019 Apr; 10(2):. PubMed ID: 31015328
[TBL] [Abstract][Full Text] [Related]
3. Drugs and drug development for chemotherapy of leprosy and tuberculosis, including M. avium infections.
Seydel JK
Trop Med Parasitol; 1990 Sep; 41(3):341-3. PubMed ID: 2255857
[No Abstract] [Full Text] [Related]
4. Ethionamide biomimetic activation and an unprecedented mechanism for its conversion into active and non-active metabolites.
Laborde J; Deraeve C; Duhayon C; Pratviel G; Bernardes-Génisson V
Org Biomol Chem; 2016 Sep; 14(37):8848-8858. PubMed ID: 27714216
[TBL] [Abstract][Full Text] [Related]
5. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
6. Prothionamide and prothionamide-S-oxide in experimental leprosy.
Matsuo Y; Tatsukawa H; Murray JF; Peters JH
Int J Lepr Other Mycobact Dis; 1981 Sep; 49(3):302-6. PubMed ID: 6459296
[No Abstract] [Full Text] [Related]
7. [GenoType MTBDR plus 1.0® for the detection of cross-resistance between isoniazide and ethionamide in isolates of multidrug-resistant Mycobacterium tuberculosis].
Rueda J; Realpe T; Mejía G; Zapata E; Robledo J
Biomedica; 2015; 35(4):541-8. PubMed ID: 26844443
[TBL] [Abstract][Full Text] [Related]
8. A review of the use of ethionamide and prothionamide in childhood tuberculosis.
Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
Tuberculosis (Edinb); 2016 Mar; 97():126-36. PubMed ID: 26586647
[TBL] [Abstract][Full Text] [Related]
9. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates.
Rueda J; Realpe T; Mejia GI; Zapata E; Rozo JC; Ferro BE; Robledo J
Antimicrob Agents Chemother; 2015 Dec; 59(12):7805-10. PubMed ID: 26369965
[TBL] [Abstract][Full Text] [Related]
10. [The problem of resistance in the treatment of Mycobacterium infections: new experimental results and combinations for the treatment of tuberculosis and leprosy].
Seydel JK; Schaper KJ
Pharm Unserer Zeit; 1995 Nov; 24(6):313-23. PubMed ID: 8592712
[No Abstract] [Full Text] [Related]
11. Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates.
Islam MM; Tan Y; Hameed HMA; Liu Z; Chhotaray C; Liu Y; Lu Z; Cai X; Tang Y; Gao Y; Surineni G; Li X; Tan S; Guo L; Cai X; Yew WW; Liu J; Zhong N; Zhang T
Clin Microbiol Infect; 2019 Aug; 25(8):1041.e1-1041.e7. PubMed ID: 30583053
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of the antituberculosis drug ethionamide.
Vale N; Gomes P; Santos HA
Curr Drug Metab; 2013 Jan; 14(1):151-8. PubMed ID: 23215813
[TBL] [Abstract][Full Text] [Related]
13. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
[TBL] [Abstract][Full Text] [Related]
14. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis.
DeBarber AE; Mdluli K; Bosman M; Bekker LG; Barry CE
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9677-82. PubMed ID: 10944230
[TBL] [Abstract][Full Text] [Related]
15. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea.
Lee H; Cho SN; Bang HE; Lee JH; Bai GH; Kim SJ; Kim JD
Int J Tuberc Lung Dis; 2000 May; 4(5):441-7. PubMed ID: 10815738
[TBL] [Abstract][Full Text] [Related]
16. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities.
Vilchèze C; Jacobs WR
Microbiol Spectr; 2014 Aug; 2(4):MGM2-0014-2013. PubMed ID: 26104204
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis.
Larsen MH; Vilchèze C; Kremer L; Besra GS; Parsons L; Salfinger M; Heifets L; Hazbon MH; Alland D; Sacchettini JC; Jacobs WR
Mol Microbiol; 2002 Oct; 46(2):453-66. PubMed ID: 12406221
[TBL] [Abstract][Full Text] [Related]
19. Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA).
Khan AM; Shawon J; Halim MA
J Mol Graph Model; 2017 Oct; 77():386-398. PubMed ID: 28957755
[TBL] [Abstract][Full Text] [Related]
20. Bacterial growth kinetics of "M. lufu" in the presence and absence of various drugs alone and in combination. A model for the development of combined chemotherapy against M. leprae?
Seydel JK; Wempe EG
Int J Lepr Other Mycobact Dis; 1982 Mar; 50(1):20-30. PubMed ID: 7042611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
